Cynthia Carlsson, MD, MS, was recently interviewed by CBS 58 News in Milwaukee about the U.S. Food and Drug Administration (FDA) approval of Leqembi (lecanemab), which showed a reduction of clinical decline in a study of people with early Alzheimer’s disease.
“What was impressive about this study is that it improved the amyloid levels in the brain, lowered those. It improved their cognition, improved their function, improved their quality of life, all of these things we really care about, as well as, what the brain looks like,” Carlsson said. Amyloid is believed to contribute to the symptoms of Alzheimer’s Disease.
UW–Madison is one of 100 research sites in the world currently offering a clinical study of the investigational treatment in people who may be at risk for memory problems. The AHEAD study is aimed at delaying memory decline in people up to 20 years before the symptoms of Alzheimer’s disease appear.
“‘New era of treating Alzheimer’s’: Wisconsin doctors, researchers celebrate FDA approval of new drug” appeared online at CBS58.com on January 6, 2023.